Pathological cardiac hypertrophy is characterized by abnormal cardiomyocyte metabolism, reduced myocardial contractility, and dysregulated synthesis of myocardial contractile proteins. This pathological process leads to progressive impairment of cardiac function and ultimately progresses to heart failure. Previous studies have demonstrated that PRMT5 exerts a significant inhibitory effect on heart failure, yet its clinical significance in the context of heart failure remains undefined. In this study, we hypothesized that serum PRMT5 may serve as a biomarker to predict cardiac structural parameters and functional indices. Therefore, we aim to analyse the correlation between serum PRMT5 levels and the following parameters-LVPWs, LVPWd, LVIDs, LVIDd, IVSTs, IVSTd, EF, FS, LVMi and RWT on the first day when participants are enrolled in this study.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
Healthy group: Aged ≥18 years (both sexes), systolic blood pressure (SBP) ≤120 mmHg and diastolic blood pressure (DBP) ≤80 mmHg, no history of cardiovascular diseases, ejection fraction (EF) ≥50%.
Heart failure group: Aged ≥18 years (both sexes), EF ≤50%.
Exclusion Criteria:
* Exclusion criteria for healthy people: people with other underlying diseases or congenital diseases are not included in the study.
* Exclusion criteria for patients with heart failure: patients with heart failure other metabolic diseases or congenital diseases were excluded from the study.
Primary outcome measure(s)
Serum PRMT5 level at baseline — Baseline (day of informed consent agreement and blood sampling) Serum PRMT5 level is analysed at the day of informed consent agreement and blood sampling
LVIDs level at baseline — Baseline Left ventricular internal diameter at systolic state is measured at the day of informed consent agreement and cardiac ultrasound examination
LVIDd level at baseline — Baseline Left ventricular internal diameter at diastolic state is measured at the day of informed consent agreement and cardiac ultrasound examination
LVPWs level at baseline — Baseline left ventricular posterior wall at systolic state is measured at the day of informed consent agreement and cardiac ultrasound examination
LVPWd level at baseline — Baseline left ventricular posterior wall at diastole state is measured at the day of informed consent agreement and cardiac ultrasound examination
IVSTs at baseline — Baseline Interventricular septum at systolic state is measured at the day of informed consent agreement and cardiac ultrasound examination
IVSTd at baseline — Baseline Interventricular septum at diastolic state is measured at the day of informed consent agreement and cardiac ultrasound examination
EF at baseline — Baseline Ejection fraction is calculated according to the formula below:
1. EF=(LVEDV-LVESV)/LVEDV\*100%;
2. LVEDV=(7.0\*LVIDd\^3)/(2.4+LVIDd)
3. LVESV=(7.0\*LVIDs\^3)/(2.4+LVIDs)
FS at baseline — Baseline Fractional shortening is calculated based on the formula below:
FS=(LVIDd-LVIDs)/LVIDd\*100%
LVMi at baseline — Baseline Left ventricular mass index is calculated according to the formula below:
1. LVMi(g/m\^2)=LVM/BSA;
2. LVM(g)=LVM=0.8×1.04×\[(LVIDd+IVSd+LVPWd)\^3-LVIDd\^3\]+0.6;
3. BSA(m\^2)=0.007184×W\^0.425×H\^0.725 (W: Weight, kg; H: Height, cm)
RWT at baseline — Baseline Relative wall thickness is calculated according to the formula below:
RWT=2\*(IVSd+LVPWd)/LVIDd
Trial sites (1)
Facility
City
Region
Status
the University of Hongkong-Shenzhen Hospital
Shenzhen
Guangdong
More The University of Hong Kong-Shenzhen Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.